MBM Wins Before the Federal Court

REPLIGEN CORPORATION v. ATTORNEY GENERAL OF CANADA
March 2011

The central argument in this judicial review of a patent decision – that was accepted by the Court – is below:

B. The Applicant’s Oral Argument at the Hearing
[24] In oral argument, he argued the Commissioner failed to properly interpret section 46 of the Act resulting in asking herself the wrong question when analyzing Repligen’s correction request. [25] He argues section 46 of the Act is clear. It obliges the owner of a patent i.e. the patentee of a patent; in French “le titulaire d’un brevet” to pay prescribed fees and it is only if and when such fees payable are not paid within the prescribed time that the term of the patent shall be deemed to have expired at the end of the prescribed time for payment.  

[26] He argues the Commissioner was wrong to say the maintenance fees were not paid by Repligen on the ‘486 patent. CPA’s payment which the Commission does not deny receiving were specifically made on behalf of the named owner Repligen. Moreover in its request for correction Counsel specifically so stated. In the circumstances of this case there was no discretion for the Commissioner to exercise, Counsel argued.  

[27] In addition, he argues there is nothing in section 46 of the Act which requires maintenance fee payments to be made by reference to the number under which the patent was issued nor is that requirement found in section 182 of the Rules. He buttressed this argument by a reference to section 7 of the Rules which provides that communications addressed to the Commissioner in relation to an application shall include the application number, if one has been assigned. He contrasted this requirement with a reference to section 182 of the Rules dealing with Maintenance Fees which does not contain a similar requirement in respect of issued patents.

Decision:
THIS COURT'S JUDGMENT is that this judicial review application is granted with costs, the Commissioner's decision is set aside and the Applicant's correction request shall be reconsidered by a different official in the Patent Office taking into account these reasons.

Read the full decision here

Submit to DiggSubmit to FacebookSubmit to Google BookmarksSubmit to StumbleuponSubmit to TwitterSubmit to LinkedIn

cb photo 91 561829f6d3c22

DR. SUZANNE HOF

Patent Agent


Suzanne focuses on the drafting and prosecuting of biochemical, pharmaceutical, chemical as well as cleantech and green technology patents.MBM read_more_btn

 

MBM logo

About MBM

 The process of invention is complete only with the IP protection provided in law. That's where MBM comes in. We match our clients' creative thinking with the creative protection needed to achieve their goals.Read More About MBM

Clarifications to the Data Protection Guidance Document

Health Canada recently announced that section 2.1 of its Guidance Document re: Data Protection has been amended to clarify that the prior approval of a medicinal ingredient in a drug for veterinary use will not preclude the granting of data protection for a drug for...Read More